BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Indeed, in the presence of glycolysis inhibitors, or in the absence of glutamine, where glucose consumption slows, the fading‐off of BCR/Ablprotein expression and signaling is delayed, so that CML stem cell potential remains TKI‐sensitive [7].